51 citations,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
25 citations,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
1 citations,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
November 2023 in “Annales de dermatologie et de vénéréologie, FMC” Baricitinib effectively treats severe alopecia for up to 104 weeks.
38 citations,
October 2014 in “British journal of dermatology/British journal of dermatology, Supplement” Bimatoprost solution is effective and safe for long-term use in treating eyelash thinning.
37 citations,
January 2010 in “International Journal of Trichology” Bimatoprost helped eyelash growth in nearly half of the patients with a type of eyelash hair loss.
16 citations,
March 2016 in “Clinical ophthalmology” Bimatoprost is safe and improves eyelash growth in healthy kids but not in those with eyelash loss from chemotherapy or alopecia.
2 citations,
February 2016 in “British Journal of Dermatology” Bimatoprost solution 0.03% is effective for treating sparse eyelashes.
6 citations,
October 2022 in “American journal of clinical dermatology” The review shows how to properly diagnose and treat the loss of eyebrow and eyelash hair.
69 citations,
April 2010 in “Clinical ophthalmology” Bimatoprost is effective for growing longer, thicker, and darker eyelashes.
May 2023 in “Dermatology and therapy” The document concludes that identifying the cause of eyebrow and eyelash loss is key to treating it and improving quality of life.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
September 2024 in “Journal of the American Academy of Dermatology” Regulatory γδ T cells help protect hair follicles from alopecia areata and promote hair regrowth.
66 citations,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
9 citations,
December 2020 in “Dermatologic Therapy” Certain drugs are effective for skin conditions like psoriasis, vitiligo, and hair loss.
1 citations,
October 2023 in “Dermatology and therapy” Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
December 2023 in “Journal of dermatology” Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
1 citations,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
72 citations,
July 2014 in “American journal of clinical dermatology” Some treatments, like corticosteroids and sensitizing agents, can help with alopecia areata, but more high-quality research is needed.
3 citations,
April 2019 in “Journal of Dermatological Treatment” Caffeine shows promise for treating some types of hair loss, but more research is needed.
1 citations,
August 2020 in “IntechOpen eBooks” Old drugs like finasteride and spironolactone are being successfully used for hair loss and skin conditions, and many other drugs show promise for new uses in dermatology.
2 citations,
December 2007 in “Expert Review of Dermatology” The document concludes that early diagnosis and treatment are key for pediatric hair loss disorders, and addressing the emotional effects on children is important.
1 citations,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
October 2022 in “The Korean Journal of Physiology and Pharmacology” Targeting the PGD2-DP2 pathway may help treat hair loss.
4 citations,
September 2011 in “Expert Review of Dermatology” Various treatments exist for alopecia areata, but none are completely satisfactory; choice depends on age, disease extent, and preference.
7 citations,
January 2021 in “Dermatology and therapy” Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.
February 2009 in “Journal of the American Academy of Dermatology” Transverse sections are better for non-scarring hair loss, vertical sections are better for lichen planopilaris, and either method works for other scarring hair loss types.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
20 citations,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.